Male Infertility Market Size, Share & Trends Analysis Report By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination), By Treatment, By Region,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

Male Infertility Market Size and Research

The male infertility market size was exhibited at USD 4.41 billion in 2024 and is projected to hit around USD 7.18 billion by 2034, growing at a CAGR of 5.0% during the forecast period 2025 to 2034.

Male Infertility Market Key Takeaways:

• The DNA fragmentation segment accounted for the largest revenue share of 21.77% in 2024.
• The ART and varicocele surgery segment dominated the market with a revenue share of 71.0% in 2024.
• In 2024, Europe dominated the market with a revenue share of 38.0%.
• Asia Pacific is expected to witness the fastest growth with a CAGR of 5.60% over the forecast period.

Report Scope of Male Infertility Market

Increasing infertility rates across the globe and the adoption of assisted reproductive technologies (ARTs) are expected to drive the market for male infertility in the forthcoming years. ARTs cover a wide spectrum of infertility treatments and offer solutions for males facing problems, such as low sperm count, abnormal sperm quality, and poor motility. Moreover, ARTs offer a high success rate as compared to medications. The market for male infertility is expected to witness significant growth in the future owing to technological advancements in the field of assisted reproductive technologies.

With the general acceptability and diagnostic techniques' ability to give an accurate analysis of sperm DNA integrity, DNA fragmentation technology is projected to grow steadily in the future. DNA fragmentation in sperm is one of the main reasons for male infertility. For diagnostic reasons, this technique is performed to diagnose male infertility. COVID-19 affected healthcare services severely. Only emergency medical procedures were allowed during the initial phase of the pandemic. The diagnostics, personal protection equipment, and critical medical supplies have seen increasing demand, while medical procedures have dropped by 50% to 60%, depending on the market.

The clinical disease generated by the SARS-CoV-2 virus, COVID-19, has been linked to a huge cytokine storm and organ system destruction. Despite the lack of evidence for SARS-CoV-2 virus detection in the testis, testicular injury and dysregulation of gonadotropins linked to inflammation have been documented in some studies. Furthermore, as a result of the pandemic's fast evolution, constantly updated medical therapies and governmental regulations that cause delays in care might affect fertility.

An increase in the global prevalence of infertility is a significant clinical problem. Around 48 million couples suffer from infertility worldwide. Of all cases, about 20% to 30% of cases are due to male factor infertility. This may be due to one or a combination of factors, such as abnormal morphology, lower sperm concentration, and poor sperm motility. Hence, increasing male infertility and growing awareness regarding the same have further prompted the use of drugs, hormonal therapy, and ART. Alcohol intake, smoking, obesity, stress, and lifestyle changes are some of the major factors that can be attributed to infertility in males. According to the National Center for Health Statistics, the fertility rate in males below 30 years has decreased globally by 15% from 2006 to 2010.

Continuous efforts in R&D are carried out for a better understanding of the idiopathic world of infertility. Hence, companies are investing in the development of devices for identifying the root cause and targeted treatment. Furthermore, the development and commercialization of hormonal therapy are likely to drive the market for male infertility during the forecast period. Governments of various countries have taken initiatives to improve the reimbursement scenario for infertility-related treatments. In addition, improved safety of patient data due to standardization of regulations is expected to increase patient preference for infertility treatments.

Male Infertility Market By Test Insights

The DNA fragmentation segment accounted for the largest revenue share of 21.77% in 2024 owing to the ability of the diagnostic techniques to provide a reliable analysis of sperm DNA integrity. Adoption of this technique is increasing in the market as sperm DNA fragmentation is a leading cause of infertility in males. Based on test, the market is segmented into DNA fragmentation technique, oxidative stress analysis, microscopic examination, sperm agglutination, computer assisted semen analysis, sperm penetration assay, and others.

Computer-assisted semen analysis is expected to witness significant growth in the coming years due to technological advancements. Semen analysis is the most preferred test for the diagnosis and it can be performed through microscopic examination techniques. For instance, in April 2018, Sandstone Diagnostics received the U.S. FDA approval to launch Trak Volume Cup, a device that allows males to measure semen volume and diagnose hypospermia at home.

Male Infertility Market By Treatment Insights

The ART and varicocele surgery segment dominated the market with a revenue share of 71.0% in 2024. The most preferred technique for the treatment of male infertility is enhancing spermatogenesis with the help of hormonal therapy for a natural pregnancy, especially among males with a low sperm count. Based on treatment, the market for male fertility is segmented into ART and varicocele surgery and medication.

ARTs are used to treat major factors responsible for male infertility, such as sperm autoantibodies, viral orchitis, epididymal dysfunction, accessory gland infection, chemotherapy, heat, trauma, and other idiopathic factors. The high cost of treatment and the requirement of several other therapy cycles are some of the major factors contributing to the segment growth. Increasing healthcare expenditure in developing countries, growing awareness about male infertility, and rising adoption in middle- and low-income countries are the key factors anticipated to drive the ART segment over the forecast period.

Male Infertility Market By Regional Insights

In 2024, Europe dominated the market with a revenue share of 38.0%. This is attributed to the availability of well-equipped and advanced fertility clinics, higher adoption of costlier treatment, better coverage for diagnosis and treatment, and high awareness level. Furthermore, healthcare spending and the availability of well-established healthcare infrastructure are contributing significantly to the regional market growth.

Asia Pacific is expected to witness the fastest growth with a CAGR of 5.60% over the forecast period. Emerging countries in the region, including India, China, and Singapore, have been witnessing strong economic growth. The Asian market is being driven by advancements in medical diagnostics as well as rising male infertility. The growing geriatric population, along with a rise in lifestyle-associated diseases, has resulted in an increase in the incidence rate of male infertility.

Some of the prominent players in the male infertility market include:

• Bayer Healthcare
• Andrology Solutions
•  Aytu BioScience, Inc.
• Cadila Healthcare Ltd.
• Halotech DNA SL
• EMD Sereno, Inc.
•  SCSA Diagnostics, Inc.
• Intas Pharmaceuticals Ltd.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the male infertility market

By Test

• DNA Fragmentation Technique
• Oxidative Stress Analysis
• Microscopic Examination
• Sperm Agglutination
• Computer Assisted Semen Analysis
• Sperm Penetration Assay
• Others

By Treatment

• Assisted Reproductive Technology and Varicocele Surgery
• Medication

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)